FOLD Amicus Therapeutics Inc

$9.56

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing and delivering drugs for people living with rare metabolic diseases. The company is headquartered in Philadelphia, Pennsylvania.

Website: https://amicusrx.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1178879
Address
1 CEDAR BROOK DRIVE, CRANBURY, NJ, US
Valuation
Market Cap
$2.10B
P/E Ratio
nan
PEG Ratio
-0.18
Price to Book
10.81
Performance
EPS
$-0.18
Dividend Yield
—
Profit Margin
-10.60%
ROE
-31.70%
Technicals
50D MA
$8.59
200D MA
$10.00
52W High
$12.65
52W Low
$6.20
Fundamentals
Shares Outstanding
307M
Target Price
$16.64
Beta
0.79

FOLD EPS Estimates vs Actual

● Estimated
● Actual

FOLD News & Sentiment

Nov 21, 2025 • Zacks Commentary SOMEWHAT-BULLISH
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
Nov 19, 2025 • Zacks Commentary SOMEWHAT-BULLISH
BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU
Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms ...
Nov 14, 2025 • Zacks Commentary SOMEWHAT-BULLISH
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
Nov 13, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.
Nov 11, 2025 • Zacks Commentary NEUTRAL
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.
Nov 10, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Wall Street Analysts Believe Amicus Therapeutics ( FOLD ) Could Rally 76.32%: Here's is How to Trade
The consensus price target hints at a 76.3% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Sentiment Snapshot

Average Sentiment Score:

0.266
50 articles with scored sentiment

Overall Sentiment:

Bullish

FOLD Reported Earnings

Jul 31, 2025
Jun 30, 2025 (Pre market)
0.12 Surprise
  • Reported EPS: $0.01
  • Estimate: $-0.11
  • Whisper: —
  • Surprise %: 109.1%
May 01, 2025
Mar 31, 2025 (Pre market)
0.1 Surprise
  • Reported EPS: $0.03
  • Estimate: $-0.07
  • Whisper: —
  • Surprise %: 142.9%
Feb 19, 2025
Dec 31, 2024 (Pre market)
-0.0 Surprise
  • Reported EPS: $0.09
  • Estimate: $0.09
  • Whisper: —
  • Surprise %: -1.2%
Nov 06, 2024
Sep 30, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.02
  • Estimate: $-0.01
  • Whisper: —
  • Surprise %: -100.0%
Aug 08, 2024
Jun 30, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $-0.05
  • Estimate: $-0.06
  • Whisper: —
  • Surprise %: 16.7%
May 09, 2024
Mar 31, 2024 (Pre market)
-0.09 Surprise
  • Reported EPS: $-0.16
  • Estimate: $-0.07
  • Whisper: —
  • Surprise %: -128.6%
Feb 28, 2024
Dec 31, 2023 (Pre market)
-0.05 Surprise
  • Reported EPS: $-0.11
  • Estimate: $-0.06
  • Whisper: —
  • Surprise %: -83.3%
Nov 08, 2023
Sep 30, 2023 (Pre market)
0.01 Surprise
  • Reported EPS: $-0.07
  • Estimate: $-0.08
  • Whisper: —
  • Surprise %: 12.5%
Aug 08, 2023
Jun 30, 2023 (Pre market)
-0.03 Surprise
  • Reported EPS: $-0.15
  • Estimate: $-0.12
  • Whisper: —
  • Surprise %: -25.0%

Financials